慢性片頭痛予防のための二重カルシトニン遺伝子関連ペプチドアンタゴニストの評価
Kara S Graves1, Jason To1, Hayley Paige2
1University of Vermont Medical Center, Burlington, Vermont, USA.
Headache
|February 13, 2026
まとめ
二重カルシトニン遺伝子関連ペプチド (CGRP) アナゴニストは,慢性片頭痛患者の頭痛の頻度と重症を著しく軽減しました. 一般的には安全ですが,有効性を確認し,潜在的な脳卒中リスクを評価するためにさらなる研究が必要です.
科学分野:
- 神経学 神経学とは
- 薬理学 薬理学とは
背景:
- 慢性的な片頭痛は数百万人に影響を及ぼし,効果的な予防戦略を必要とします.
- カルチトニン遺伝子関連ペプチド (CGRP) 反抗剤は,急性および予防的な片頭痛治療のために確立されています.
- 2つの予防的なCGRP剤を同時に使用する安全性と有効性は,ほとんど未調査のままです.
研究 の 目的:
- 慢性片頭痛を患っている成人におけるカルシトニン遺伝子関連ペプチド (CGRP) 反抗体による二重予防療法の安全性と有効性を評価する.
- 併用CGRPアンタゴニストの使用に関連した頭痛の頻度,重度,および有害事象の変化を評価する.
主な方法:
- 慢性的な片頭痛を患う37人の成人を対象に,1つのCGRPモノクローナル抗体と1つの経口ゲパントを用いた遡及的なコホート研究を行いました.
- 双重CGRPアンタゴニスト療法を開始する前と後の毎月の頭痛日を比較した前後分析.
- 重度の頭痛の日,有害事象,および中止率を含む二次結果の評価.
主要な成果:
- 月々の頭痛日数 (p=0.031) と重度の頭痛/片頭痛日数 (p<0.001) の有意な減少が観察されました.
- 患者の22%は,頭痛の日に少なくとも50%の減少を達成しました.
- 副作用の有意な増加は認められませんでしたが,リスク因子のある患者で1回の缺血性脳卒中が発生しました. 51%が費用か利益の欠如のために治療を中止した.
結論:
- 二重のCGRP抗体療法では,他の治療法に耐性のある慢性片頭痛患者の選択に利点がある可能性があります.
- より大規模で多様な集団を対象とした更なる前向きな研究は,有効性を確認し,脳卒中などの潜在的なリスクを調査するために正当化されています.
関連する概念動画
Synthesis and Functions of Calcitonin
4.8K
Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
4.8K
Peptide Bonds
83.6K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.6K
Cancer Prevention
8.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
8.2K
Cholinergic Antagonists: Pharmacokinetics
992
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
992
Cholinergic Antagonists: Therapeutic Uses
1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Prevention of Further Absorption of Poison
1.3K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.3K


